Gene Expression Control Using Micro-Trace Element Compounds During C.A.M. and Conventional Cancer Protocols
OBJECTIVES:
- To utilize multiple naturally-occurring micro-trace element compounds to sequester
exogenous estrogens from multiple sources, including environmental and metabolic
sources, and eliminate them from the body prior to influencing prostate, breast, and
uterine cancer pathways.
- To utilize specific naturally-occurring flavonoids to suppress
proliferation-stimulating activities induced by normal metabolism and environmental
estrogen, estrogen-mimicking, and testosterone compounds.
- To utilize DPPH radical-scavenging activity to reduce secondary bonding of TMPRSS2-ERG
fusing and negative-bonded environmental estrogen.
- To utilize a full diet of specifically grown inclusion produce to maintain normal
metabolic function.
OUTLINE: Patients are randomized to 1 of 2 arms.
- Arm I: Patients receive oral natural supplements comprising indole-3-carbinol, perillyl
alcohol, glucuronic acid, and flavonoids daily for 12 months. Patients also consume
whole foods comprising indole-3-carbinol and a diet that eliminates exogenous growth
hormones.
- Arm II: Patients do not receive natural supplements or consume whole foods or a special
diet.
Levels of compounds of interest are measured by inductively-coupled plasma mass
spectrometry, high performance liquid chromatography, gas chromatography, and
matrix-assisted laser desorption/ionization time of flight mass spectrometry.
After completion of study therapy, patients are followed periodically for 6 months.
Interventional
Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Sequestration and elimination of exogenous estrogens from the body using multiple naturally-occurring micro-trace element compounds
lowering body estrogens as related to hormone driven cancer
6 months
No
Richard E. Lasker, PhD
Principal Investigator
Brabant Research
United States: Institutional Review Board
CDR0000643461
NCT00910884
November 2013
July 2014
Name | Location |
---|---|
Brabant Research, Incorporated | Monroe, Washington 98272 |